BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/24/2026 6:27:54 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-26 01:45 |
|
Peer-Review Started |
|
2025-12-26 01:45 |
|
First Decision by Editorial Office Director |
|
2026-01-06 08:49 |
|
Return for Revision |
|
2026-01-06 08:49 |
|
Revised |
|
2026-01-23 09:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-02 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-02 10:31 |
|
Articles in Press |
|
2026-03-02 10:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-17 02:52 |
|
Publish the Manuscript Online |
|
2026-03-24 06:27 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Study |
| Article Title |
Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ammar Chapra, Fateen Ata, Amal Abdellatif, Mohammed Nofal, Ahmed Daniyal, Asma Mohammad Younus, Jassim Zaheen Shah and Kakil Rasul |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fateen Ata, Academic Fellow, MD, Principal Investigator, Department of Internal Medicine, Cleveland Clinic Foundation, 9500, Cleveland Clinic, Cleveland, OH 44118, United States. docfateenata@gmail.com |
| Key Words |
Immune checkpoint inhibitors; Cardiotoxicity; Myocarditis; Pericarditis; Cardiomyopathy; Heart failure; Middle East; Qatar; Pembrolizumab |
| Core Tip |
Immune checkpoint inhibitors (ICIs) have revolutionized treatments and outcomes in oncology, but can cause serious ICI-related cardiac adverse events. This first comprehensive Middle Eastern study revealed that delayed-onset heart failure, rather than myocarditis, predominated among affected patients, with pembrolizumab being the most common implicated ICI. The 2.1% incidence and high mortality necessiates the need for early cardiac surveillance and risk stratification. |
| Publish Date |
2026-03-24 06:27 |
| Citation |
Chapra A, Ata F, Abdellatif A, Nofal M, Daniyal A, Mohammad Younus A, Shah JZ, Rasul K. Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East. World J Clin Cases 2026; 14(9): 118187 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i9/118187.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i9.118187 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
